Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Alectinib + Ixazomib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Alectinib||Alecensa||CH5424802|RO5424802||ALK Inhibitor 31 RET Inhibitor 52||Alecensa (alectinib) is an inhibitor of RET and ALK, including ALK fusions and the gatekeeper mutation, L1196M (PMID: 21575866, PMID: 25349307). Alecensa (alectinib) is FDA-approved for use in patients with ALK-positive (rearrangements and fusions) non-small cell lung cancer (FDA.gov).|
|Ixazomib||Ninlaro||MLN9708||Ninlaro (ixazomib) inhibits proteosome activity, resulting in accumulation of misfolded proteins, inhibition of pathway signaling, and potentially leading to cell death (PMID: 20160034). Ninlaro (ixazomib) in combination with Revlimid (lenalidomide) and dexamethasone is FDA approved for use in patients with multiple myeloma who have received at least one prior therapy (FDA.gov)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|EML4 - ALK TP53 V274fs||lung non-small cell carcinoma||sensitive||Alectinib + Ixazomib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, the combination therapy of Alecensa (alectinib) and Ninlaro (ixazomib) inhibited the proliferation of non-small cell lung cancer cells harboring EML4-ALK and TP53 Q331* in culture and resulted in tumor regression in cell line xenograft models, with 3/8 achieving complete tumor regression (PMID: 33310890).||33310890|
|EML4 - ALK TP53 Q331*||lung non-small cell carcinoma||sensitive||Alectinib + Ixazomib||Preclinical - Cell culture||Actionable||In a preclinical study, the combination therapy of Alecensa (alectinib) and Ninlaro (ixazomib) inhibited the proliferation of non-small cell lung cancer cells harboring EML4-ALK and TP53 Q331* in culture (PMID: 33310890).||33310890|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|